by Thomas Lethenborg | Jan 27, 2016 | Press releases
Copenhagen, Denmark – 27 January 2015. Monsenso, a Copenhagen-based technology company, announced today that UK-based, St Andrew’s Healthcare, will implement a new mHealth solution for borderline and depression patients. The mHealth solution, designed and developed by Monsenso, will be used to support the person-centred treatment of inpatients.
Thomas Lethenborg, CEO at Monsenso ApS, said that St Andrew’s will conduct a six-month service evaluation feasibility study to determine if the mHealth solution for borderline and depression patients should also be used to help treat other mental health illnesses.
“St Andrew’s Healthcare has a commitment to providing the best inpatient and outpatient mental health services in the UK. With the implementation of the Monsenso mHealth solution, clinicians will have access to patient’s historical aggregated data that will help clinical staff in the treatment of complex mental health illnesses,” Mr Lethenborg added.
St Andrew’s Healthcare Director of Nursing and Quality, Lesley Boswell said the trial would allow them to investigate how real-time mood monitoring could be used to enhance patient care.
“We are continuously looking to improve our understanding of patient experiences and this technology will help us to access previously hidden mood signals. With a bit of configuration, our aim is to use the technology to help support the therapies and treatment we currently provide to our patients, with views to expanding the programme to other care pathways in the future,” said Ms Boswell.
The Monsenso mHealth solution for borderline and depression is based on a double-loop treatment model. On one side, patients use a smartphone to fill in routine self-assessments that reveal their current state of mind and collect sensor data. The smartphone app also works as a self-management tool that allows patients to manage their symptoms and the behaviours that trigger those symptoms.
On the other side, clinicians use a web portal where they can access all the data collected by the patients’ smartphones anytime, anywhere. The web portal enables clinicians to view relevant information related to each patient.
With more than 4000 employees, St Andrew’s Healthcare delivers effective treatment, therapies, clinical consultancy, vocational rehabilitation and outpatient care across its four sites. The charity provides specialist and secure care pathways in mental health and neuropsychiatry and provides care for young people, adults, and seniors.
For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com
Bonnie Sleeman
Communications Coordinator
St Andrew’s Healthcare
+44 1604 872946
bsleeman@standrew.co.uk You can download this article as PDF in English and Danish
by Thomas Lethenborg | Jan 25, 2016 | News, Press releases
Copenhagen, Denmark – 25 January 2016. Monsenso ApS, a Copenhagen-based technology company, has been granted 1.575 million DKK to continue the research and development of the existing data-driven, cloud-based, mHealth solution for anxiety and borderline treatment.
The ENTER project (previously called E-Mental project), which has been granted an overall budget of 19 million DKK, is being done in collaboration with The Mental Health Services in the Region of Southern Denmark (MHS), the South Denmark University, Aalborg University, Context Consulting and Monsenso. Monsenso will be involved in two studies for the E-mental project:
The Anxiety Monitoring Study
The objective of the study is to implement and validate the Monsenso mHealth solution for anxiety disorders.
Mobile monitoring solutions can be useful in assisting patients in using skills learned during treatment in real life situations, as well as to monitor and give feedback on progress or lack of progress during therapy. This feedback leads to better outcomes for patients not responding well to treatment.
The mDIARY Study for patients with borderline personality disorder
The objective of the study is to prove that the Monsenso DBT (Dialectical Behavioural Therapy) solution is a reliable and clinically valid way to collect patient data, helping individuals learn these skills at home, speeding up their recovery.
The study will include a three-month pilot study where a randomized percentage of the patients will use either paper-based diary cards or the Monsenso mHealth app. Additionally, the study will also include a two-year randomized controlled trial. During this part of the study, half of the patients will be given an mHealth app that includes coaching suggestions while the second half will use paper-based self-assessments. The number of missing data will be compared, and data quality of the app versus established clinical measures will be evaluated. User satisfaction will be assessed with focus group interviews.
Additionally, a cost-effectiveness study will run in parallel to the main research. The objective of this study is to estimate the economic advantages of implementing the proposed e-mental health solution in the healthcare system.
E-mental health solutions have the potential to reduce the cost of treatment and to enable a larger number of people to be treated. The economic aspects should be adequately investigated with regards to cost-effectiveness as well as financial aspects of implementation in clinical practice. The study aims to determine the cost-effectiveness of Internet interventions compared to the most cost-effective treatment currently available.
With regards to the support obtained from the Innovation Fund, Thomas Lethenborg, CEO at Monsenso commented, “The mHealth solution developed by Monsenso has the potential to revolutionize the treatment of psychiatric illnesses. The support received from the Innovation Fund will provide us with the necessary evidence to validate our solution clinically and financially for the treatment of mental illnesses.”
To learn more click on this link:
For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com You can download this article as PDF in English
by Thomas Lethenborg | Dec 1, 2015 | Press releases
Copenhagen, Denmark – 1 December 2015. Monsenso Aps, an innovation leader in mobile health (mHealth) solutions for mental health, announced today the acquisition of DayBuilder Solutions, a local competitor developing an mHealth solution for depression to strengthen focus on mHealth for mental health.
The acquisition will consolidate Monsenso in the Danish market and strengthen their focus internationally. Starting from today, Monsenso will take over DayBuilder’s obligations to customers and researchers. Besides acquiring new customers with this merger, Monsenso will also benefit from additional research and technology that will support the future development of leading mobile health solutions for mental health.
With regards to the merger, Thomas Lethenborg, CEO at Monsenso, commented, “With this merger, two evolving Danish companies can now present a unified front locally and internationally, rather than being competitors. This merger has made us a stronger player in the development space of mHealth solutions; therefore, clinicians and patients will benefit from this outcome.”
“I believe that Monsenso has the capability to dominate the market nationally and internationally, and with our joint efforts we have the potential to help thousands of people suffering from mental illness worldwide,” commented Philip Kaare Løventoft, CEO at DayBuilder Solutions.
After the merger is completed, Monsenso will take over a new research project called SAFE2, which was handled by DayBuilder Solutions in collaboration with Rigshospitalet, the University Hospital in Denmark.
Currently, the Monsenso mHealth solution is being used by the different health care regions in Denmark to support the treatment of patients suffering from schizophrenia, major depressive disorder(MDD), post-traumatic stress disorder (PTSD), anxiety, and borderline personality disorder.
For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com You can download this article as PDF in English and Danish
